MSA
TVRD

Mason Street Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Mason Street Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,761
Closed -$532K – 1927
2014
Q3 		$532K Buy
+1,761
New +$723K ﹤0.01% 1337

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DPA
Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Mason Street Advisors's TVRD Position: Q4 2014 in Review

Mason Street Advisors sold out of Tvardi Therapeutics (TVRD) in Q4 2014, closing a stake of 1,761 shares — an estimated $532K sold.

Mason Street Advisors first reported a position in TVRD in Q3 2014 and held it in 1 quarter. The position peaked at $532K in Q3 2014. 56 funds tracked by Wall St. Rank hold TVRD as of Q4 2014.

  • Mason Street Advisors reported no remaining Tvardi Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Mason Street Advisors sold 1,761 Tvardi Therapeutics shares in Q4 2014, an estimated $532K.
  • Mason Street Advisors first reported a position in Tvardi Therapeutics in Q3 2014 and held it in 1 quarter.
  • Mason Street Advisors's Tvardi Therapeutics position peaked at $532K in Q3 2014.
  • 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2014.

Based on Mason Street Advisors's 13F filing for Q4 2014, filed 13 Feb 2015.